Business
Krystal Biotech to Present Pre-clinical Data Highlighting KB301 for Aesthetic Indications at the ASDS 2020 Virtual Meeting
- KB301 is designed to deliver a full-length human type 3 collagen transgene via injection - The Phase 1 PEARL-1 clinical study to evaluate KB301 in acne
About this update from Krystal Biotech, Inc.
[{"type":"text","content":"\n- KB301 is designed to deliver a full-length human type 3 collagen transgene via injection \n\n- The Phase 1 PEARL-1 clinical study to evaluate KB301 in acne scars and fine wrinkles is currently enrolling \n\n PITTSBURGH--(BUSINESS WIRE)--\nKrystal Biotech, Inc. (Nasdaq:KRYS) today announced the presentation of positive preclinical data supporting the ongoing development of KB301, an innovative, investigational therapy designed to reverse the decline of collagen in aging skin. The data will be presented at the American Society for Dermatologic Surgery (ASDS) 2020 Virtual Meeting to be held October 9-11, 2020.\n\nThe preclinical program evaluated KB301’s ability to transduce clinically relevant skin cells, to express and secrete mature human COL3 in vitro, as well as to confirm proper tissue localization of the transgene without toxicity or systemic vector distribution in vivo.\n\nKey findings from the poster presentation titled In Vitro and In Vivo Pharmacology of KB301, an HSV-1-Based Gene Therapy, for the Treatment of Superficial Skin Depressions include:\n\n\nIn vitro, KB301 readily transduced primary aged male and female human dermal fibroblasts (HDFs) and induced full-length COL3 expression, proper maturation, and subsequent secretion.\n\n\nIn vivo, successful vector transduction and subsequent COL3 expression was observed in a dose-dependent manner at both the transcript and protein levels in young and aged immunocompetent mice. COL3 was found to be properly localized to the mouse dermis.\n\n\nHigh concentrations of KB301 were non-cytotoxic to the cells in vitro, supporting safety of the vector. In vivo, no vector was detected in blood or other tested tissues, showing that KB301 was retained in the treated area of the skin.\n\n\nThe above data presentation will be available on the Scientific Publications page of the Company’s website at http://ir.krystalbio.com/select-scientific-publications.\n\nAbout collagen type III and KB301\n\nThe skin is composed of collagen-rich connective tissue composed primarily of types I and III collagen fibrils. Age-related changes in skin are largely due to aberrant collagen homeostasis, caused both by intrinsic (e.g., passage of time, genetics) and extrinsic (e.g., chronic light exposure, pollution) factors, which leads to progressive loss of dermal collagen. KB301 is an investigational th...